2017
Reply to Anthony et al., “Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment”
Fofana M, Dowdy D. Reply to Anthony et al., “Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment”. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00427-17. PMID: 28539499, PMCID: PMC5444152, DOI: 10.1128/aac.00427-17.Commentaries, Editorials and LettersA Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents And Chemotherapy 2017, 61: 10.1128/aac.00498-16. PMID: 27956422, PMCID: PMC5328532, DOI: 10.1128/aac.00498-16.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsBayes TheoremBiological AvailabilityComputer SimulationDrug Administration ScheduleDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFluoroquinolonesHumansMicrobial Sensitivity TestsModels, StatisticalMycobacterium tuberculosisPyrazinamideRifampinTuberculosis, PulmonaryConceptsCompanion drugsExtensively Drug-Resistant TuberculosisSecond-line treatmentFirst-line treatmentSecond-line regimensDrug-resistant tuberculosisUse of pyrazinamideExtensive drug resistanceDrug resistance dataEmergence of strainsEmergence of mutationsXDR-TBSequential regimensHIV infectionAlternative drugsResistance amplificationPyrazinamide resistanceProlonged treatmentCombination antimicrobialsDrug resistanceInfectious diseasesPrevalenceProportion of simulationsAppropriate useRegimens
2015
The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis
Knight GM, Colijn C, Shrestha S, Fofana M, Cobelens F, White RG, Dowdy DW, Cohen T. The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis. Clinical Infectious Diseases 2015, 61: s147-s154. PMID: 26409276, PMCID: PMC4583567, DOI: 10.1093/cid/civ579.Peer-Reviewed Original Research
2014
Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
Fofana MO, Knight GM, Gomez GB, White RG, Dowdy DW. Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis. PLOS ONE 2014, 9: e96389. PMID: 24816692, PMCID: PMC4015982, DOI: 10.1371/journal.pone.0096389.Peer-Reviewed Original ResearchConceptsShort-course regimensTB incidenceTreatment completionTreatment successFirst-line treatment regimensFour-month regimenFour-month regimensLower treatment completionProportion of patientsPopulation-level incidenceSix-month therapyGlobal tuberculosis incidenceDynamic transmission modelPopulation-level transmissionCourse regimensTB diseaseTB patientsNew regimensRelapse rateTB mortalityTB transmissionTreatment regimensTuberculosis incidenceClinical trialsRegimens
2013
Cost-effectiveness of novel first-line treatment regimens for tuberculosis
Owens JP, Fofana MO, Dowdy DW. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 590-596. PMID: 23575322, PMCID: PMC3844288, DOI: 10.5588/ijtld.12.0776.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsFirst-line treatmentStandard treatmentTotal disability-adjusted life yearsFailure/relapseShort-course regimensFirst-line regimensFirst-line drugsHigher drug costsHealth care perspectiveDrug pricesTB patientsActive tuberculosisNovel regimensPatient cohortDrug costsEqual efficacyRegimensLife yearsCare perspectiveTuberculosisRelapsePatientsTreatmentShort duration